Esperion Therapeutics (ESPR) Expected to Announce Earnings on Tuesday

Esperion Therapeutics (NASDAQ:ESPR) is projected to announce its Q4 2025 results before the market opens on Tuesday, March 3rd. Analysts expect the company to announce earnings of $0.16 per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, March 10, 2026 at 8:00 AM ET.

Esperion Therapeutics Trading Down 0.3%

Shares of ESPR opened at $3.35 on Friday. Esperion Therapeutics has a 52 week low of $0.69 and a 52 week high of $4.18. The firm has a market cap of $800.85 million, a price-to-earnings ratio of -6.70, a PEG ratio of 0.70 and a beta of 1.09. The stock has a 50 day moving average of $3.49 and a 200-day moving average of $3.10.

Analysts Set New Price Targets

A number of research firms have commented on ESPR. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. Piper Sandler initiated coverage on shares of Esperion Therapeutics in a research report on Tuesday, November 25th. They issued an “overweight” rating and a $9.00 price target on the stock. Wall Street Zen lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Citigroup reiterated a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Esperion Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $8.00.

Insider Activity at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the sale, the chief financial officer owned 467,525 shares of the company’s stock, valued at $1,715,816.75. This trade represents a 1.55% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 15,543 shares of company stock worth $55,709 in the last three months. 1.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Kestra Advisory Services LLC acquired a new stake in shares of Esperion Therapeutics in the fourth quarter valued at approximately $35,000. Captrust Financial Advisors bought a new position in Esperion Therapeutics in the 4th quarter worth approximately $40,000. Cibc World Markets Corp acquired a new stake in Esperion Therapeutics in the 4th quarter valued at approximately $57,000. Hudson Bay Capital Management LP bought a new stake in Esperion Therapeutics during the 4th quarter valued at $67,000. Finally, CIBC Bancorp USA Inc. bought a new stake in Esperion Therapeutics during the 3rd quarter valued at $56,000. Institutional investors own 47.39% of the company’s stock.

About Esperion Therapeutics

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.